Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.
Investors 2
Mentions in press and media 2
| Date | Title | Description |
| 08.10.2024 | City Therapeutics Raises $135M in Series A Financing | City Therapeutics, a Cambridge, MA-based biopharmaceutical company which specializes in RNA interference (RNAi)-based medicine, raised $135M in Series A funding.
The round was led by ARCH Venture Partners with participation from Fidelity Ma... |
| - | City Therapeutics | “City Therapeutics” |
Reviews 0
